NorthWest Biotherapeutics Inc (NWBO)

[longusa]

Hi Pyrr, 16k for -L volume manufacturing aligns with my calc derived from the DNDN financials. That would be for all doses for a give patient, whether 3 yrs or more, as the marginal cost of each dose is minimal (1 syringe and a few seconds of machine time).

Another factor occurred to me since the earlier dialogue: an additional complexity in the NW case is that Cognate is the manufacturer and will margin the cost for their own financial success, so the cost seen by NW will be the Cognate price. If Cognate wants 50% GM, then the cost seen by NW will be 2x the manufacturing cost, or 32k in volume, but likely 60k-90k up front in low volume. This suggests an initial price of >100k would be indicated.

Hopefully, the Cognate margin is already pat of the Jan 2014 agreements entered into between NW and Cognate.

This also may be a complicating factor in the HE pricing discussions, where Fraunhofer is manufacturing the doses; no idea if Fraunhofer would want/be allowed to margin the cost. Again hopefully this was already negotiated when the NW-Fraunhofer contracts were entered into, so there is a cost certain to base the InEK conversation on.